Mesenchymal stem cell-derived exosomes as a new drug carrier for the treatment of spinal cord injury: A review
10.1016/j.cjtee.2024.03.009
- VernacularTitle:Mesenchymal stem cell-derived exosomes as a new drug carrier for the treatment of spinal cord injury: A review
- Author:
Lin-Fei CHENG
1
;
Chao-Qun YOU
;
Cheng PENG
;
Jia-Ji REN
;
Kai GUO
;
Tie-Long LIU
Author Information
1. Medical College, Anhui University of Science and Technology, Huainan, 232000, Anhui province, China
- Keywords:
Spinal cord injury;
Mesenchymal stem cell;
Exosomes;
Mechanism;
Drug carrier
- From:
Chinese Journal of Traumatology
2024;27(3):134-146
- CountryChina
- Language:Chinese
-
Abstract:
Spinal cord injury (SCI) is a devastating traumatic disease seriously impairing the quality of life in patients. Expectations to allow the hopeless central nervous system to repair itself after injury are unfeasible. Developing new approaches to regenerate the central nervous system is still the priority. Exosomes derived from mesenchymal stem cells (MSC-Exo) have been proven to robustly quench the inflammatory response or oxidative stress and curb neuronal apoptosis and autophagy following SCI, which are the key processes to rescue damaged spinal cord neurons and restore their functions. Nonetheless, MSC-Exo in SCI received scant attention. In this review, we reviewed our previous work and other studies to summarize the roles of MSC-Exo in SCI and its underlying mechanisms. Furthermore, we also focus on the application of exosomes as drug carrier in SCI. In particular, it combs the advantages of exosomes as a drug carrier for SCI, imaging advantages, drug types, loading methods, etc., which provides the latest progress for exosomes in the treatment of SCI, especially drug carrier.
